Mumbai: Investors’ eyes are set on Rubicon Research Ltd. as the pharmaceutical firm prepares to make its stock market debut this week. Following a robust subscription, the company’s initial public offering (IPO) is poised to generate substantial listing gains for early investors.

The Rubicon Research IPO closed with an overwhelming response on Monday, with the final day of bidding seeing the issue oversubscribed 103.90 times. Investors placed bids for 1,70,96,80,620 shares against the 1,64,55,670 shares on offer, reflecting strong market appetite for the pharmaceutical company’s equity.

The share allotment status was finalised on Tuesday, October 14, allowing successful bidders to expect their shares credited to demat accounts on Wednesday, October 15. Market participants have been clo

See Full Page